Cargando…

Prevention of COPD exacerbations: medications and other controversies

Exacerbations have significant impact on the morbidity and mortality of patients with chronic obstructive pulmonary disease. Most guidelines emphasise prevention of exacerbations by treatment with long-acting bronchodilators and/or anti-inflammatory drugs. Whereas most of this treatment is evidence-...

Descripción completa

Detalles Bibliográficos
Autores principales: Vestbo, Jørgen, Lange, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5005132/
https://www.ncbi.nlm.nih.gov/pubmed/27730132
http://dx.doi.org/10.1183/23120541.00011-2015
_version_ 1782450866253463552
author Vestbo, Jørgen
Lange, Peter
author_facet Vestbo, Jørgen
Lange, Peter
author_sort Vestbo, Jørgen
collection PubMed
description Exacerbations have significant impact on the morbidity and mortality of patients with chronic obstructive pulmonary disease. Most guidelines emphasise prevention of exacerbations by treatment with long-acting bronchodilators and/or anti-inflammatory drugs. Whereas most of this treatment is evidence-based, it is clear that patients differ regarding the nature of exacerbations and are likely to benefit differently from different types of treatment. In this short review, we wish to highlight this, suggest a first step in differentiating pharmacological exacerbation prevention and call for more studies in this area. Finally, we wish to highlight that there are perhaps easier ways of achieving similar success in exacerbation prevention using nonpharmacological tools.
format Online
Article
Text
id pubmed-5005132
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-50051322016-10-11 Prevention of COPD exacerbations: medications and other controversies Vestbo, Jørgen Lange, Peter ERJ Open Res Reviews Exacerbations have significant impact on the morbidity and mortality of patients with chronic obstructive pulmonary disease. Most guidelines emphasise prevention of exacerbations by treatment with long-acting bronchodilators and/or anti-inflammatory drugs. Whereas most of this treatment is evidence-based, it is clear that patients differ regarding the nature of exacerbations and are likely to benefit differently from different types of treatment. In this short review, we wish to highlight this, suggest a first step in differentiating pharmacological exacerbation prevention and call for more studies in this area. Finally, we wish to highlight that there are perhaps easier ways of achieving similar success in exacerbation prevention using nonpharmacological tools. European Respiratory Society 2015-05-06 /pmc/articles/PMC5005132/ /pubmed/27730132 http://dx.doi.org/10.1183/23120541.00011-2015 Text en Copyright ©ERS 2015 http://creativecommons.org/licenses/by-nc/4.0/ This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
spellingShingle Reviews
Vestbo, Jørgen
Lange, Peter
Prevention of COPD exacerbations: medications and other controversies
title Prevention of COPD exacerbations: medications and other controversies
title_full Prevention of COPD exacerbations: medications and other controversies
title_fullStr Prevention of COPD exacerbations: medications and other controversies
title_full_unstemmed Prevention of COPD exacerbations: medications and other controversies
title_short Prevention of COPD exacerbations: medications and other controversies
title_sort prevention of copd exacerbations: medications and other controversies
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5005132/
https://www.ncbi.nlm.nih.gov/pubmed/27730132
http://dx.doi.org/10.1183/23120541.00011-2015
work_keys_str_mv AT vestbojørgen preventionofcopdexacerbationsmedicationsandothercontroversies
AT langepeter preventionofcopdexacerbationsmedicationsandothercontroversies